Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
J Assoc Physicians India ; 67(4): 68-73, 2019 Apr.
Article in English | MEDLINE | ID: mdl-31311222

ABSTRACT

The progress in the understanding of inflammatory muscle diseases over the past several decades has been slow but steady. The classification given by Bohan and Peter's in 1975 was based on clinical features. It served well, but inadequacies were also obvious. The increasing discoveries of autoantibodies in this group of disorders have helped in refining the classification of Bohan and Peter's to a large extent. At the present state of knowledge, it is now possible to classify and sub-classify this group of diseases using distinct clinical features combined with the type of autoantibodies in well-defined subsets. Not only the subsets help predicting the type of organ involvement and comorbidities but may also help choose a specific drug for a particular subclass. This approach may lead to the practice of precision medicine for inflammatory myositis.


Subject(s)
Myositis , Precision Medicine , Autoantibodies , Comorbidity , Humans , Knowledge
2.
Indian J Med Res ; 148(3): 263-278, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30425216

ABSTRACT

A young physician starting a fresh career in medicine in this millennium would hardly stop to think about the genesis of a particular biological drug that he/she will be prescribing for a patient evaluated in the morning outpatient department. For him/her, this is now routine, and the question of 'Who', 'How' and 'When' about these biologicals would be the last thing on their mind. However, for those who came to the medical profession in the 1950s, 1960s and 1970s, these targeted drugs are nothing short of 'miracles'. It would be a fascinating story for the young doctor to learn about the long journey that the dedicated biomedical scientists of yesteryears took to reach the final destination of producing such wonder drugs. The story is much like an interesting novel, full of twists and turns, heart-breaking failures and glorious successes. The biologicals acting as 'targeted therapy' have not only changed the natural history of a large number of incurable/uncontrollable diseases but have also transformed the whole approach towards drug development. From the classical empirical process, there is now a complete shift towards understanding the disease pathobiology focusing on the dysregulated molecule(s), targeting them with greater precision and aiming for better results. Seminal advances in understanding the disease mechanism, development of remarkably effective new technologies, greater knowledge of the human genome and genetic medicine have all made it possible to reach the stage where artificially developed 'targeted' drugs are now therapeutically used in routine clinical medicine.


Subject(s)
Drug Development/history , Molecular Targeted Therapy/history , Biological Products/history , Biological Products/pharmacology , History, 20th Century , History, 21st Century , Humans
3.
Clin Rheumatol ; 37(9): 2331-2340, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29696436

ABSTRACT

To compare the prevalence of cardiovascular disease (CVD) and major CVD risk factors among rheumatoid arthritis (RA) patients enrolled in a large US and multinational registry. We compared CVD and CVD risk factor prevalence from 11 countries enrolled in the CORRONA US and CORRONA International registries; patients from the 10 ex-US participating countries were grouped by region (Eastern Europe, Latin America, and India). Unadjusted summary data were presented for demographics and disease characteristics; comparisons for prevalence of CVD risk factors and CVD were age/gender standardized to the age/gender distribution of the US enrolled patients. Overall, 25,987 patients were included in this analysis. Compared to patients from the ex-US regions, US participants had longer disease duration and lower disease activity, yet were more likely to receive a biologic agent. Additionally, CORRONA US participants had the highest body mass index (BMI). Enrolled patients in India had the lowest BMI, were more rarely smokers, and had a low prevalence of hyperlipidemia, hypertension, and prior CVD compared to the US and other ex-US regions. Participants from Eastern Europe had a higher prevalence of hypertension and hyperlipidemia and highest prevalence of all manifestations of CVD. Differences in the prevalence of both CVD and major CVD risk factors were observed across the four regions investigated. Observed differences may be influenced by variations in both non-modifiable/modifiable characteristics of patient populations, and may contribute to heterogeneity on the observed safety of investigational and approved therapies in studies involving RA patients from different origins.


Subject(s)
Arthritis, Rheumatoid/epidemiology , Cardiovascular Diseases/epidemiology , Argentina/epidemiology , Arthritis, Rheumatoid/therapy , Brazil/epidemiology , Cross-Sectional Studies , Europe, Eastern/epidemiology , Female , Humans , Hyperlipidemias/epidemiology , Hypertension/epidemiology , India/epidemiology , Male , Mexico/epidemiology , Prevalence , Prospective Studies , Registries , Risk Factors , United States/epidemiology
4.
Int J Rheum Dis ; 21(8): 1563-1571, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29345081

ABSTRACT

AIM: To test the validity of an augmented tuberculosis skin test (a-TST) combined with Quantiferon TB-gold® (QFTG) test for the screening of latent tuberculosis infection (LTBI) in patients with rheumatoid arthritis (RA) being considered for treatment with biologic disease-modifying anti-rheumatic drugs or targeted synthetic disease-modifying anti-rheumatic drugs. METHOD: Standard TST using 1 tuberculin unit (TU) of purified protein derivative (PPD, RT23 strain) was carried out. If the positivity was less as compared to the general population, then a-TST using 10 TU PPD was employed. Simultaneously, QFTG test was also performed. RESULTS: Using standard TST, 6/44 (13.6%), patients were positive compared to the reported figures of ~ 40% of the general population; 38 of the remaining TST-negative patients were then given an a-TST with 10 TU PPD; eight of them dropped out. Of the remaining 30 patients, eight (26.6%) were positive. Another 70 patients tested directly with a-TST; 22 (31.4%) were found positive. Thus, of a total of 100 patients tested with a-TST, 30 (30%) were positive. In 54 a-TST negative patients, QFTG was done; seven (13%) were positive. Thus, in combined a-TST with QFTG, 43% of the RA patients were found positive, suggestive of the presence of LTBI. CONCLUSION: Combined a-TST with QFTG testing gave 43% positivity among RA patients, which is close to the reported ~ 40% Mantoux positivity in the general population. Therefore, this method for the screening of LTBI in Indian patients with RA being considered for tumor necrosis factor alpha treatment could be satisfactory for offsetting TB flare. It may apply to other high-burden TB countries around the world.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Products/therapeutic use , Immunocompromised Host , Interferon-gamma Release Tests , Latent Tuberculosis/diagnosis , Tuberculin Test , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/epidemiology , Arthritis, Rheumatoid/immunology , Biological Products/adverse effects , Humans , India/epidemiology , Latent Tuberculosis/epidemiology , Latent Tuberculosis/immunology , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology
6.
Int J Rheumatol ; 2017: 1824794, 2017.
Article in English | MEDLINE | ID: mdl-28555158

ABSTRACT

Since 1984 the diagnosis of ankylosing spondylitis (AS) has been based upon the modified New York (mNY) criteria with mandatory presence of radiographic sacroiliitis, without which the diagnosis is not tenable. However, it may take years or decades for radiographic sacroiliitis to develop delaying the diagnosis for long periods. It did not matter in the past because no effective treatment was available. However, with the availability of a highly effective treatment, namely, tumour necrosis factor-α inhibitors (TNFi), the issue of early diagnosis of AS acquired an urgency. The Assessment of SpondyloArthritis International Society (ASAS) classification criteria published in 2009 was a significant step towards this goal. These criteria described an early stage of the disease where sacroiliitis was demonstrable only on MRI but not on standard radiograph. Therefore, this stage of the disease was labelled "nonradiographic axial SpA" (nr-axSpA). But questions have been raised if, in search of early diagnosis, specificity was compromised. The Federal Drug Administration (FDA, USA) withheld approval for the use of TNFi in patients with nr-axSpA because of issues related to the specificity of these criteria. This review attempts to clarify some of these aspects of the nr-axSpA-AS relationship and also tries to answer the question whether ASAS classifiable radiographic axial spondyloarthritis (r-axSpA) term can be interchangeably used with the term AS.

8.
Stud Health Technol Inform ; 245: 1264, 2017.
Article in English | MEDLINE | ID: mdl-29295349

ABSTRACT

Data entry remains the slowest link in the value chain inhibiting growth of Electronic Medical Records and attendant benefits towards Meaningful use. We designed templates for user forms customized by specialty. Here, we demonstrate the functionality of our software and provide instructions on how these can be adopted by other developers.


Subject(s)
Electronic Health Records , Meaningful Use , Software , Humans , Medical Records Systems, Computerized
9.
Curr Rheumatol Rev ; 12(3): 168-176, 2016.
Article in English | MEDLINE | ID: mdl-27964706

ABSTRACT

Methotrexate (MTX) was synthesised as a folate antagonist for use in treating childhood leukaemia in 1940s. Gubner and colleagues in 1953 used several log-order lower doses of MTX that mimicked the anti-inflammatory properties of cortisone. They used it successfully in treating rheumatoid arthritis (RA). Their work was however overlooked because the Nobel Prize winning drug cortisone held sway in those days. With increasing awareness of the adverse effects of cortisone, interest was rekindled in discovering 'steroid-sparing' drugs. Hoffmeister and Willkens used low-dose MTX (LD-MTX) in treating RA patients in 1960s with impressive results. Pivotal trials in 1984-5 established the efficacy and safety of LD-MTX in treating RA that gained FDA approval in 1988. LD-MTX at doses <25-30 mg weekly as mini-pulses, is presently the standard-of-care for the treatment of RA. Its toxicities and adverse effects are rarely if ever life-threatening. This is in contrast to the high-dose methotrexate (HD-MTX) for treating malignancies at doses that are several log-orders higher and usually cause serious toxicities. While LD-MTX acts mainly as an anti-inflammatory drug by increasing tissue adenosine levels besides other mechanisms, HD-MTX has anti-proliferative cytotoxic action with different toxicity profile and adverse effects. In practical terms LD-MTX and HD-MTX are 2 different therapeutic agents. However, in developing countries like India the stigma attached to MTX as a cytotoxic 'cancer drug' still persists and most non-rheumatologists fear its use in RA. This review aims to allay such anxiety attached to LD-MTX so that they start using it in appropriate doses for treating RA.


Subject(s)
Antirheumatic Agents/administration & dosage , Arthritis, Rheumatoid/drug therapy , Methotrexate/administration & dosage , Dose-Response Relationship, Drug , Humans , Rheumatology/methods
10.
Int J Rheum Dis ; 19(9): 844-51, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27293066

ABSTRACT

This review highlights the story of how methotrexate (MTX), a drug discovered for the treatment of childhood leukemia, became the mainstay of treatment and the standard-of-care for rheumatoid arthritis (RA) and was also found useful for several additional related rheumatological diseases. As against several synthetic disease-modifying antirheumatic drugs (csDMARDs) for treating RA that were discovered serendipitously, the use of low-dose MTX (LD-MTX) was based on sound reasoning and astute observations made in the 1940s and 1950s. The difference between high-dose MTX (HD-MTX) used in the treatment of childhood leukaemia and other malignancies as against LD-MTX used in rheumatology is emphasized.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Drug Discovery , Methotrexate/therapeutic use , Rheumatology , Animals , Antimetabolites, Antineoplastic/therapeutic use , Antirheumatic Agents/adverse effects , Antirheumatic Agents/history , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/history , Drug Discovery/history , History, 20th Century , Humans , Methotrexate/adverse effects , Methotrexate/history , Rheumatology/history , Treatment Outcome
11.
Clin Rheumatol ; 35(9): 2163-73, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27122121

ABSTRACT

This study was conducted in order to study (a) seropositive RA patients for their prior caregivers, diagnosis makers, drugs and doses taken and (b) the disease status at the first visit and the last visit, from the standpoint of whether they received optimum or suboptimum DMARD treatment. Prospectively entered data were extracted from a rheumatology-specific electronic health record for demography, diagnostic delay, prior caregivers, diagnosis makers, intake of DMARDs and glucocorticoids and disease activity state at first presentation and at the last visit using structured query language. Among 316 patients, prior caregivers were orthopaedicians (73.4 %), alternative systems of medicine practitioners (62 %), internists (38 %), rheumatologists (35.8 %), general practitioners (17 %) and others (12 %). The diagnosis of RA was made by rheumatologists (55.6 %), orthopaedicians (21 %), internists (12.6 %), physiotherapists (3.5 %), homeopaths (2.8 %), general practitioner (2.1 %), neurologists (1.4 %) and Ayurvedic physicians (0.7 %). The mean and the median diagnostic delay among 142 patients where information was available were 18 and 8.5 months, respectively (SD +23.2). Thirty-two percent of the patients had early disease, 48 % established disease and 20 % late disease at presentation. Sixty-six percent of the patients had taken DMARDs-methotrexate (56 %), hydroxychloroquine (46.2 %), leflunomide (18.7 %) and sulfasalazine (20.6 %)-and often in combinations. Different preparations, doses and schedules of glucocorticoids were taken orally or parentally by 51 %. Only one (0.3 %) patient had taken biological DMARDs prior to visiting this clinic. High or moderate disease activity was present in 84 % at the first clinic visit that fell to 14 % at the last clinic visit. The majority of patients with RA were treated by orthopaedicians and practitioners of alternative systems of medicine with only a third by rheumatologists. In 80 % of patients, the diagnosis was made 18 months at the onset, yet in 84 %, the disease control was poor. Non-use or suboptimal use of methotrexate appeared to be the main reason.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Methotrexate/therapeutic use , Aged , Antirheumatic Agents/administration & dosage , Arthritis, Rheumatoid/diagnosis , Delayed Diagnosis , Drug Therapy, Combination , Female , Glucocorticoids/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , India , Male , Methotrexate/administration & dosage , Middle Aged , Sulfasalazine/therapeutic use , Treatment Outcome
12.
Int J Rheum Dis ; 18(7): 736-41, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26172961

ABSTRACT

AIM: Comparison of ankylosing spondylitis (AS) with non-radiographic axial spondyloarthritis (nr-axSpA) classified with the recent ASsessment of spondyloArthritis International Society (ASAS) criteria. PATIENTS & METHODS: This study included 288 patients clinically diagnosed as having spondyloarthritis (SpA) where a satisfactory radiograph of sacroiliac (S-I) joints was available. The AS and the nr-axSpA groups were compared for the various SpA-related variables. RESULTS: Of 288 axSpA patients, there were 187 with AS. Of the remaining 101 patients without radiographic sacroiliitis, S-I joint magnetic resonance imaging (MRI) was available in 72; 54 of them showed active sacroiliitis thus classified as nr-axSpA according to the ASAS criteria. The remaining 18 patients with normal MRI and the other 29 patients without MRI of the S-I joints (total 47 patients), were classified as nr-axSpA using the 'clinical arm' of the ASAS criteria. On comparing the 187 AS with 101 patients in the nr-axSpA group, the AS group showed significantly more males, longer disease duration, more axial symptoms at disease onset, higher Bath Ankylosing Spondylitis Metrology Index and more syndesmophytes. Biologicals were offered significantly more often to the AS group but methotrexate as monotherapy or in combination with other disease-modifying anti-rheumatic drugs was offered more often in nr-axSpA group. There was no statistically significant difference between AS and nr-axSpA in other SpA parameters. CONCLUSION: The differences brought out between AS and nr-axSpA groups show that they may not be the same disease. A prospective long-term follow-up of large cohorts may help in clarifying if nr-axSpA is simply an early stage in the spectrum of SpA evolving into AS over time or is there inherent difference between them.


Subject(s)
Outpatient Clinics, Hospital , Sacroiliac Joint , Sacroiliitis/diagnosis , Spondylarthritis/diagnosis , Spondylitis, Ankylosing/diagnosis , Adolescent , Adult , Antirheumatic Agents/therapeutic use , Female , Humans , India/epidemiology , Magnetic Resonance Imaging , Male , Predictive Value of Tests , Prognosis , Radiography , Retrospective Studies , Sacroiliac Joint/diagnostic imaging , Sacroiliac Joint/drug effects , Sacroiliitis/classification , Sacroiliitis/diagnostic imaging , Sacroiliitis/drug therapy , Sacroiliitis/epidemiology , Severity of Illness Index , Spondylarthritis/classification , Spondylarthritis/diagnostic imaging , Spondylarthritis/drug therapy , Spondylarthritis/epidemiology , Spondylitis, Ankylosing/classification , Spondylitis, Ankylosing/diagnostic imaging , Spondylitis, Ankylosing/drug therapy , Spondylitis, Ankylosing/epidemiology , Time Factors , Young Adult
15.
Curr Rheumatol Rep ; 16(4): 413, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24515283

ABSTRACT

This article summarises the available information on seronegative arthritides from South Asian countries, namely India, Pakistan, Bangladesh, Sri Lanka, Nepal, and Bhutan. The diseases described are spondyloarthritides (SpA), including ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), inflammatory bowel disease-related arthritis (IBDa), enthesitis-related arthritis (ERA) of the paediatric age group, and undifferentiated spondyloarthritis (uSpA). Relevant information on SpA from South Asia is scarce. However, the available publications indicate that these are commonly seen conditions. HLA-B27 is present in approximately 6-8 % of the normal population in the Indian subcontinent. In the SpA group, HLA-B27 has the highest frequency in AS patients (>90 %) and the lowest in PsA patients. Clinical features are similar to those reported in standard textbooks, but with a few exceptions: e.g., in South Asian countries ERA is the most common subset of juvenile idiopathic arthritis (JIA), whereas in the West the most common subset of JIA is oligoarthritis. Poverty is a major challenge in treating these diseases in South Asia; with poor health insurance coverage, only a few patients are able to afford biological treatment. Therefore, rheumatologists have attempted novel treatment strategies for those with an unsatisfactory response to standard non-steroidal anti-inflammatory drugs (NSAIDs) or coxibs.


Subject(s)
Spondylarthritis/epidemiology , Antirheumatic Agents/therapeutic use , Asia, Western/epidemiology , Genetic Predisposition to Disease , HLA-B27 Antigen/genetics , Humans , Prohibitins , Spondylarthritis/diagnosis , Spondylarthritis/drug therapy , Spondylarthritis/genetics
16.
Best Pract Res Clin Rheumatol ; 28(6): 960-72, 2014 Dec.
Article in English | MEDLINE | ID: mdl-26096096

ABSTRACT

In recent years, the cost of health care around the world has risen at a rate that is deemed unsustainable. It has been estimated that 20% of this could be saved by rationalising laboratory investigations and reducing inappropriate requisitioning of the investigations. There are several reasons for the excessive, redundant, inappropriate or unnecessary investigations and procedures, which in some instances are unethical practices. The impact in financial terms is more in developing countries such as India with <5% of the population having medical insurance and hardly any other third-party payer system. The 'Choosing Wisely' campaign of the American Board of Internal Medicine, Canadian Rheumatology Association's Choosing Wisely Committee and the 'Society for Less Investigative Medicine' (SLIM) initiative of the doctors of All-India Institute of Medical Sciences (AIIMS), New Delhi, all have provided recommendations to reduce unnecessary investigations, and these are among some of the efforts to reduce the cost of investigations without compromising the quality of care.


Subject(s)
Delivery of Health Care/organization & administration , Developing Countries/economics , Health Care Costs , Cost-Benefit Analysis , Delivery of Health Care/economics , Humans , Physicians/organization & administration
17.
J Assoc Physicians India ; 59: 87-90, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21751642

ABSTRACT

OBJECTIVES: To analyse patients presenting with acute inflammatory ankle arthritis from an aetiological standpoint; whether they had Löfgren's syndrome (acute presentation of sarcoidosis), or Poncet's disease (reactive arthritis due to tuberculosis infection). An additional objective was to establish a simple, practical yet optimal algorithm for diagnostic approach and management of such patients. METHODS: The study included 18 patients from northern India presenting with isolated acute inflammatory ankle arthritis. A combination of complete clinical evaluation, Mantoux test and contrast-enhanced computerised tomography (CE-CT) of the chest was carried out and results analysed. RESULTS: Among 18 patients presenting as inflammatory ankle arthritis is was possible to classify 10 of them as Löfgren's syndrome all of whom had negative Mantoux test and bilateral hilar lymphadenopathy without central necrosis. The other 8 patients could be classified as Poncet's disease as all of them had positive Mantoux test and showed mediastinal lymphadenopathy with or without unilateral hilar lymph nodes, with central necrosis. Finally, appropriate drug treatment (glucocorticoids with glucocorticoid-sparing drugs methotrexate and hydroxychloroquine in patients with Löfgren's syndrome; standard anti-tuberculosis drugs in Poncet's disease) gave excellent clinical response and patients remained well over a period of 1 year of follow-up. CONCLUSION: Investigated on standard lines without any invasive procedure, patients with isolated inflammatory ankle arthritis could be classified in 2 distinct categories namely: (1) Löfgren's syndrome in its complete (with EN) or incomplete (without EN) form; (2) Poncet's disease. Appropriate treatment gave satisfactory response and patients remained well over a period of 1 year of follow-up.


Subject(s)
Ankle Joint , Arthritis, Reactive/diagnosis , Arthritis/diagnosis , Erythema Nodosum/diagnosis , Sarcoidosis/diagnosis , Tuberculosis, Osteoarticular/diagnosis , Acute Disease , Adult , Algorithms , Antirheumatic Agents/therapeutic use , Antitubercular Agents/therapeutic use , Arthritis/drug therapy , Arthritis, Reactive/drug therapy , Diagnosis, Differential , Erythema Nodosum/microbiology , Female , Humans , India , Male , Middle Aged , Sarcoidosis/drug therapy , Syndrome , Tomography, X-Ray Computed , Treatment Outcome , Tuberculosis, Osteoarticular/drug therapy
18.
Int J Rheum Dis ; 14(1): 98-104, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21303489

ABSTRACT

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune connective tissue disease with protean manifestations. Most often it presents with mucocutaneous, musculoskeletal or renal involvement. In comparison, gastrointestinal (GI) manifestations of SLE are far less common. The case presented here highlights the differential diagnosis of GI manifestations of SLE that range from non-life-threatening to serious life-threatening complications, including some of the complications of on-going drug treatments. While some of them present as 'acute abdomen', others are more subacute or chronic, yet serious enough to be life-threatening. The serious GI manifestations of SLE include mesenteric vasculitis causing perforation or hemorrhage with peritonitis, acute pancreatitis and intestinal pseudo-obstruction. The patient in this paper had clinical features, imaging findings and laboratory parameters that helped the treating physician to narrow down the diagnostic possibilities and finally, in making the diagnosis of lupus-pancreatitis. She was treated with intravenous 'bolus' (i.v.-pulse) methylprednisolone for 3 days, i.v.-pulse cyclophosphamide 750 mg (one dose) along with oral methylprednisolone and other supportive measures including blood transfusions. This led to prompt and complete recovery.


Subject(s)
Abdomen, Acute/diagnosis , Lupus Erythematosus, Systemic/diagnosis , Pancreatitis/diagnosis , Abdomen, Acute/complications , Abdomen, Acute/therapy , Administration, Oral , Blood Transfusion , Cyclophosphamide/therapeutic use , Diagnosis, Differential , Drug Therapy, Combination , Female , Gastrointestinal Diseases/diagnosis , Humans , Injections, Intravenous , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/therapy , Methylprednisolone/therapeutic use , Middle Aged , Pancreatitis/complications , Pancreatitis/therapy , Tomography, X-Ray Computed , Treatment Outcome
19.
Int J Rheum Dis ; 13(4): 288-93, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21199463

ABSTRACT

Methotrexate (MTX) was originally synthesised as an anti-cancer drug. Soon it was also used in immunoinflammatory diseases, mainly in the field of rheumatology. However, the dose used in oncology is several-fold higher as compared to the dose used in systemic immunoinflammatory rheumatological diseases. This led to the use of terms 'low-dose MTX' (LD-MTX) and 'high-dose MTX' (HD-MTX) respectively for its use in immunoinflammatory rheumatological diseases as against its use in oncology. Extensive studies have demonstrated that therapeutic action, clinical indications, adverse effects and mechanisms of action of LD-MTX and HD-MTX are quite different. It is somewhat akin to low-dose aspirin versus high-dose aspirin with entirely different spectra of therapeutic action and adverse effects. It is important to understand this difference. This would help in allaying unfounded fear of adverse effects of LD-MTX that is often mistakenly considered the same as that of HD-MTX used in oncology.


Subject(s)
Antineoplastic Agents/administration & dosage , Antirheumatic Agents/administration & dosage , Methotrexate/administration & dosage , Rheumatic Diseases/drug therapy , Antineoplastic Agents/adverse effects , Antirheumatic Agents/adverse effects , Dose-Response Relationship, Drug , Humans , Methotrexate/adverse effects , Rheumatic Diseases/immunology , Risk Assessment , Terminology as Topic , Treatment Outcome
20.
Int J Rheum Dis ; 13(4): 347-60, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21199470

ABSTRACT

OBJECTIVES: To make a rheumatology-specific electronic medical record (EMR) application for easy clinical data entry, automated display of outcome measures in real-time that generates well laid-out print-outs; and provides an easily retrievable database for clinical analysis and research. METHODS: Highly labour-intensive 'MS-WORD ' template used earlier provided the basic framework for developing rheumatology-EMR applications. The authors, a rheumatologist and a soft tissue surgeon with expertise in developing medical software, successfully created a rheumatology-EMR application over a period of 2½ years using the same basic flow of work as used in the old 'MS-WORD ' template. RESULTS: The resulting EMR application form has a standard medical record documenting demographic data, complete diagnosis, appropriate dates, visit number, disease status, history, physical examination, investigations, follow-up and prescription page (with automatic updates wherever applicable). Mathematical calculations required for outcome measures (DAS, DAS28, CDAI, SDAI, AS-DAS, BASDAI, BASFI, BASMI, SLE-DAI and others) are embedded in the software, with automated updating as the examination of the musculoskeletal system proceeds in real time. Following implementation of this EMR application, more patients are being seen, patient waiting lists have been reduced; more time is available for academic and teaching work, without compromising the quality of notes, and print-outs for patients. Data retrieval has simplified clinical research with increased numbers of abstracts being presented and research papers being published. CONCLUSION: Healthcare workers with understanding of the basic principles of computers and softwares should interact with software engineers who are either themselves medical doctors or are familiar with the workflow and clinical evaluation processes to create an efficient speciality-specific EMR application.


Subject(s)
Data Display , Electronic Health Records , Hospital Information Systems , Rheumatic Diseases , Rheumatology/methods , Ambulatory Care Facilities , Appointments and Schedules , Automation , Cooperative Behavior , Data Mining , Drug Prescriptions , Health Status Indicators , Hospitals, Special , Humans , India , Interdisciplinary Communication , Predictive Value of Tests , Rheumatic Diseases/diagnosis , Rheumatic Diseases/drug therapy , Software Design , Time Management , User-Computer Interface , Waiting Lists , Workflow
SELECTION OF CITATIONS
SEARCH DETAIL
...